Toward a new understanding of attention-deficit hyperactivity disorder: Advances in research and treatment

CNS Drugs

Volumn 23, Issue SUPPL. 1, 2009, Pages 5-8

  Spencer, Thomas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ATOMOXETINE; CLONIDINE; GUANFACINE; METHYLPHENIDATE; MODAFINIL; PLACEBO; PSYCHOSTIMULANT AGENT;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPOTENSION; MAJOR DEPRESSION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; OPPOSITIONAL DEFIANT DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; SEDATION; SUBSTANCE ABUSE; TREATMENT RESPONSE; VASODILATATION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOMEDICAL RESEARCH; HUMANS;

EID: 67849098813     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-200923000-00002     Document Type: Editorial

References (34)

1. Busch B, Biederman J, Cohen LG, et al. Correlates of ADHD among children in pediatric and psychiatric clinics. Psychiatr Serv 2002; 53: 1103-11
2. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996; 53: 437-46
3. Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 1996; 35: 1193-204
4. Spencer TJ. Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms. CNS Drugs 2009; 23 Suppl. 1: 9-20
5. Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652-8
6. Biederman J, Petty CR, Dolan C, et al. The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study. Psychol Med 2008; 21: 1-10
7. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 1119-27
8. Santosh PJ, Baird G, Pityaratstian N, et al. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 2006; 32: 575-83
9. Scheffer RE, Kowatch RA, Carmody T, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005; 162: 58-64
10. Newcorn JH, Kratochvil CJ, Allen AJ, et al., for the Atomoxetine/ Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165: 721-30
11. Adderall XR. Prescribing information. Wayne (PA): Shire Pharmaceuticals, Inc., 2007
12. Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 2008; 11: 470-81
13. Concerta. Prescribing information. Mountain View (CA): ALZA Corporation, 2007
14. Adler LA, Barkley RA, Newcorn JH, et al. Managing ADHD in children, adolescents, and adults with comorbid anxiety. J Clin Psychiatry 2007; 68: 451-62
15. Strattera. Prescribing information. Indianapolis (IN): Eli Lilly & Company, 2007
16. Scahill L, Pachler M. Treatment of hyperactivity in children with pervasive developmental disorders. J Child Adolesc Psychiatr Nurs 2007; 20: 59-62
17. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009; 23 Suppl. 1: 21-31
18. Arnsten AFT. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23 Suppl. 1: 33-41
19. Stuss DT, Knight RT. Principles of frontal lobe function. Oxford University Press, Cary, NC, 2002
20. Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex 2007; 17 Suppl. 1: i6-15
21. Bobb AJ, Addington AM, Sidransky E, et al. Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 67-72
22. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1313-23
23. Tahir E, Yazgan Y, Cirakoglu B, et al. Association and linkage of DRD4 and DRD5 with attention deficit hyper-activity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry 2000; 5: 396-404
24. Buschman TJ, Miller EK. Top-down versus bottom-up control of attention in the prefrontal and posterior parietal cortices. Science 2007; 315: 1860-2
25. Knight RT, Staines WR, Swick D, et al. Prefrontal cortex regulates inhibition and excitation in distributed neural networks. Acta Psychol (Amst) 1999; 101: 159-78
26. Scahill L. Alpha-2 Adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23 Suppl. 1: 43-49
27. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121: e73-84
28. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1551-9
29. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 50-4
30. Palumbo DR, Sallee FR, Pelham Jr WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 180-8
31. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158: 1067-74
32. Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/ hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47: 189-98
33. Jakala P, Riekkinen M, Sirvio J, et al. Clonidine, but not guanfacine, impairs choice reaction time performance in young healthy volunteers. Neuropsychopharmacology 1999; 21: 495-502
34. Spiegel R, DeVos JE. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. Br J Clin Pharmacol 1980; 10 Suppl. 1: 165S-8S